Navin Fluorine Q1 FY 2026-27 Results: Net Profit Doubles To ₹243 Crore, Revenue Climbs 44%

Speciality chemicals maker Navin Fluorine began FY 2026-27 with firm demand across its core businesses, particularly the fast-growing Contract Development and Manufacturing Organisation (CDMO) division. Better operating leverage during the quarter also translated into healthier margins, helping the company deliver a much stronger bottom line than it did a year ago.

The company's June-quarter earnings reflected broad-based growth rather than gains from a single business line. Revenue crossed the ₹1,000-crore mark for the first time in a June quarter, while operating profit expanded at a faster pace than revenue as profitability improved across the portfolio.

Key Highlights

• Revenue from Operations: ₹1,045.08 crore (up 44% YoY)

• Net Profit: ₹243.31 crore (up 108% YoY)

• Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBITDA): ₹357.07 crore (up 73% YoY)

• EBITDA Margin: 34.2% (up 566 bps YoY)

• Dividend: Not announced

• CDMO Revenue: ₹180 crore (up 82% YoY)

• High-Performance Products Revenue: ₹540 crore (up 33% YoY)

• Speciality Chemicals Revenue: ₹325 crore (up 48% YoY)

How Did The Business Perform?

According to the Navin Fluorine Q1 FY 2026-27 results, consolidated net profit stood at ₹243.31 crore, compared with ₹117.16 crore in the corresponding period last year. Revenue from operations increased to ₹1,045.08 crore, while EBITDA rose to ₹357.07 crore, lifting the operating margin to 34.2% from 28.5% a year earlier.

CDMO revenue climbed 82% compared with the same period last year as demand improved for existing commercial molecules. The company also continued to deepen its relationship with a major European CDMO partner while expanding its portfolio across therapy areas such as oncology, respiratory, cardiovascular, neurology and animal health.

The High-Performance Products (HPP) business generated ₹540 crore in revenue, benefiting from stronger volumes and better product realisations. Meanwhile, the Speciality Chemicals segment posted 48% year-on-year growth to ₹325 crore, supported by healthy order visibility and higher production of existing molecules.

Navin Fluorine also said work on the second phase of its cGMP-4 expansion project, involving an investment of ₹125 crore, remains on schedule and is expected to become operational by the fourth quarter of FY27.

Management Commentary

The company did not provide a detailed management quote with its quarterly earnings announcement. However, it highlighted that demand remained healthy across its commercial molecule portfolio and that it continues to strengthen its partnership with a leading European CDMO customer.

Navin Fluorine also reiterated that its cGMP-4 expansion is progressing as planned and is expected to support future growth in its CDMO business.

Market Reaction

Ahead of the earnings announcement, Navin Fluorine’s share price ended Wednesday's session 0.12% lower at ₹7,620. Investors will closely watch the stock after the company reported strong revenue growth, margin expansion and a sharp increase in quarterly profit.

Also Read - Stocks To Watch On 6 August